Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Xenetic Biosciences Q3 EPS $(0.69) Beats $(1.12) Estimate, Sales $611.17K Beat $460.00K Estimate

Author: Benzinga Newsdesk | November 10, 2023 09:44am

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(1.12) by 38.39 percent. This is a 15 percent decrease over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $611.17 thousand which beat the analyst consensus estimate of $460.00 thousand by 32.86 percent. This is a 47.54 percent increase over sales of $414.25 thousand the same period last year.

Posted In: XBIO